ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

polyethylene glycol-recombinant human growth hormone

Also written as “PEG-rhGH Injection”, “PEG-rhGH low dose” and “PEG-rhGH high dose”.

Its studies are mostly in Turner Syndrome, led by Changchun GeneScience Pharmaceutical.

Furthest: phase 2, since Jun 13, 20172 company-led studies, 1 open or runningNext primary completion: Dec 23, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical21 open or runningphase 2since Jun 13, 2017Jun 13, 2017Dec 23, 2026phase 2 · NCT07260500

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2017First study: phase 2 study in Turner SyndromeFirst studyNCT03189160 · 180 enrolled · China
  2. Nov 21, 2025Phase 2 study in Short Stature Children Born Small for Gestational Age (SGA)NCT07260500 · 72 planned · China

Ahead

  1. Dec 23, 2026Primary completion: phase 2 study in Short Stature Children Born Small for Gestational Age (SGA)NCT07260500

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07260500Short Stature Children Born Small for Gestational Age (SGA) · China2RecruitingDec 23, 202672
NCT03189160Turner Syndrome · China2UNKNOWNMar 2018180

How it is read

Names in the registry

  • “PEG-rhGH Injection”, 1 entry
  • “PEG-rhGH low dose”, 1 entry
  • “PEG-rhGH high dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.